Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 251 to 275 of 2520

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerHTG719
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Artificial intelligence (AI)-derived software to help clinical decision making in strokeHTG708
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Twin and triplet pregnancyNG137
Kurin Lock for blood culture collectionMTG77
GaitSmart rehabilitation exercise programme for gait and mobility issuesMTG78
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Desflurane for maintenance of anaesthesiaES41

Results per page

  1. 10
  2. 25
  3. 50
  4. All